Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03839771
Title	A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)
Acronym	HOVON150AML
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications	acute myeloid leukemia myelodysplastic syndrome
Therapies	Ivosidenib Enasidenib
Age Groups:	adult \| senior
Covered Countries	SWE \| NOR \| NLD \| LUX \| LTU \| IRL \| FRA \| FIN \| EST \| ESP \| DEU \| CHE \| BEL \| AUT \| AUS